Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.45 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16987269 | 0.76 | AKR1C3 (0.44) | LMNASMN1; SMN2KDM4EHTTALDH1A1 | |
| SCHEMBL16911082 | 0.75 | NPC1 (0.40) | RAB9ALMNAPTGS1PTGS2KDM4E | |
| SCHEMBL21084563 | 0.75 | RAB9A (0.53) | RAB9AMAPKAPK2CNR1SMN1; SMN2KDM4E | |
| SCHEMBL16202085 | 0.74 | NOTUM (0.47) | RAB9ALMNASMN1; SMN2KDM4EHTT | |
| SCHEMBL679848 | 0.74 | SMN1; SMN2 (0.55) | RAB9APTGS2SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL22073083 | 0.72 | DYRK1A (0.52) | RAB9APTGS2SMN1; SMN2KDM4ENPC1 | |
| SCHEMBL13140014 | 0.71 | MEN1 (0.47) | RAB9AMAPKAPK2MEN1KMT2ANPC1 | |
| SCHEMBL13118061 | 0.71 | L3MBTL1 (0.50) | RAB9AMAPKAPK2LMNASMN1; SMN2KDM4E | |
| SCHEMBL12345146 | 0.71 | ACHE (0.54) | RAB9APTGS2SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL23402266 | 0.70 | P2RX7 (0.47) | RAB9AMAPKAPK2CNR1CNR2GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900654-B1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9554576-B2 | Tetrazolinone compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160183529-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9314023-B2 | Tetrazolinone compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150223460-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150223460-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | CYCS, MT-CO3, OXER1 | RAB9A 1175/4885MAPKAPK2 4066/4885CNR1 248/4885 |
| US-20160183529-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | CYP51A1, TCOF1, DDT | RAB9A 1692/4885MAPKAPK2 1921/4885CNR1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.